Rapid Dose Therapeutics Corp.
DOSE
CNSX
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 68.58% | 90.94% | 102.33% | 98.28% | 51.97% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 68.58% | 90.94% | 102.33% | 98.28% | 51.97% |
| Cost of Revenue | 106.88% | 135.33% | 150.87% | 106.51% | 18.59% |
| Gross Profit | 42.65% | 62.58% | 73.04% | 92.43% | 87.71% |
| SG&A Expenses | -7.57% | 15.06% | 45.35% | 98.43% | 64.47% |
| Depreciation & Amortization | 13.78% | -25.61% | -51.72% | -63.68% | -46.49% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.63% | 14.84% | 31.48% | 54.67% | 40.16% |
| Operating Income | 25.31% | 12.20% | -6.70% | -39.35% | -35.91% |
| Income Before Tax | 26.79% | 17.35% | 6.27% | -21.13% | -60.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 26.79% | 17.35% | 6.27% | -21.13% | -60.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.79% | 17.35% | 6.27% | -21.13% | -60.18% |
| EBIT | 25.31% | 12.20% | -6.70% | -39.35% | -35.91% |
| EBITDA | 23.92% | 7.42% | -17.70% | -63.69% | -63.42% |
| EPS Basic | 25.83% | 18.57% | 18.05% | -3.97% | -40.63% |
| Normalized Basic EPS | 16.92% | 8.25% | 6.99% | -19.51% | -26.42% |
| EPS Diluted | 25.83% | 18.57% | 18.05% | -3.97% | -40.63% |
| Normalized Diluted EPS | 16.92% | 8.25% | 6.99% | -19.51% | -26.42% |
| Average Basic Shares Outstanding | -1.56% | 1.27% | 15.04% | 17.78% | 15.68% |
| Average Diluted Shares Outstanding | -1.56% | 1.27% | 15.04% | 17.78% | 15.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |